234 filings
Page 2 of 12
8-K
ko7t 9wp9ddv1
12 Aug 21
Casi Pharmaceuticals Announces Second Quarter 2021
4:32pm
8-K
44qf 4bbaf
28 Jul 21
Departure of Directors or Certain Officers
4:01pm
8-K/A
pend1
21 Jun 21
Departure of Directors or Certain Officers
5:26pm
8-K
t9k71mf661a70 3pds1
16 Jun 21
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
5snae
13 May 21
Casi Pharmaceuticals Announces First Quarter 2021 Financial Results
4:02pm
8-K
wiv9arzjst11mi18z5rm
30 Apr 21
Departure of Directors or Certain Officers
4:01pm
8-K
a4itb
30 Mar 21
Announces Full Year 2020 Financial Results
12:00am
8-K
bj300
26 Mar 21
Casi Pharmaceuticals Announces Proposed Public Offering of Common Stock
4:01pm
8-K
z4tf0jq nq
25 Mar 21
Departure of Directors or Certain Officers
4:01pm
8-K
9v0fq9 jyo
23 Mar 21
Other Events
4:04pm
8-K
rr7gg2 3j
12 Mar 21
Corporate Presentation March 2021
9:20am
8-K
t2alvrpp41ck fe7
8 Mar 21
Entry into a Material Definitive Agreement
4:01pm
8-K
v0g1pc12b4a2zm0fmv
16 Feb 21
Casi Pharmaceuticals Announces Preliminary Fourth Quarter and Full-Year 2020 Revenues
4:01pm
8-K
b5vhjk5
10 Feb 21
Amendments to Articles of Incorporation or Bylaws
5:04pm
8-K
tou52wh2 wny5i9a9qt2
28 Jan 21
Casi Pharmaceuticals Partner, Bioinvent, Presents
4:02pm
8-K
uxiqyei
23 Dec 20
Receives China Breakthrough Therapy Designation
4:01pm
8-K
v7b 99fgatz9u442
16 Dec 20
Casi Pharmaceuticals Announces Appointment of Chief Financial Officer
4:43pm
8-K
a2n2h7y2355sny3b
19 Nov 20
Casi Pharmaceuticals Announces Partner Juventas
4:05pm
8-K
ettkcaqdai4p ab1
9 Nov 20
Casi Pharmaceuticals Announces Third Quarter 2020
4:30pm
8-K
o4gd00 kwi
28 Oct 20
Entry into a Material Definitive Agreement
4:26pm